B
Biomea Fusion
Creating an entirely new generation of precision medicine against genetically defined diseases
About Biomea Fusion
Biomea Fusion, Inc. is a biotechnology company focused on developing novel covalent small molecule therapies to treat serious and life-threatening diseases. Founded in 2017 by a team of experienced biotech executives, the company leverages its expertise in drug design and operational execution to create innovative medicines. Biomea Fusion operates in the pharmaceutical and biotechnology market, serving patients with aggressive tumors and other severe conditions. The company's business model involves in-house discovery and development of covalent inhibitors, which are designed to provide long-lasting therapeutic effects with minimal drug application, thereby reducing the burden on patients. Biomea Fusion generates revenue through the development and commercialization of its proprietary drug candidates, which are currently in preclinical and clinical stages. The company is committed to collaboration and inclusivity, aiming to create patient-friendly therapies that offer durable responses.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2017
- Headquarters
- San Carlos, United States
- Listing
- IPO 2021
- Employees
- 61
- Open positions
- None listed
- Dealroom signal
- 29.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Oct 2025 | $25M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jun 2025 | $40M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$70M | — |
| 2025 | $0 | — | −$98M | — |
| 2024 | $0 | — | −$142M | — |
| 2023 | $0 | — | −$125M | — |
| 2022 | $0 | — | −$84M | — |
| 2021 | — | — | −$42M | — |
| 2020 | — | — | −$5.3M | — |
Growth signals
Latest recorded traffic for Biomea Fusion is 6.9K monthly website visits, down 1.4% over the last three months. Biomea Fusion's team declined 12.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Cormorant Asset Management
Logos Capital
Aisling Capital
Rock Springs Capital
Boxer Capital
RTW Investments
Janus Henderson Investors
Point Sur Investors
Other known investors1 additional known investor
MBC Biolabs
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Biomea Fusion on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biomea Fusion’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.